Publications by authors named "S Schnittman"
Importance: In a mechanistic substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) randomized clinical trial, pitavastatin reduced noncalcified plaque (NCP) volume, but specific protein and gene pathways contributing to changes in coronary plaque remain unknown.
Objective: To use targeted discovery proteomics and transcriptomics approaches to interrogate biological pathways beyond low-density lipoprotein cholesterol (LDL-C), relating statin outcomes to reduce NCP volume and promote plaque stabilization among people with HIV (PWH).
Design, Setting, And Participants: This was a post hoc analysis of the double-blind, placebo-controlled, REPRIEVE randomized clinical trial.
Article Synopsis
- A study on the effects of statin therapy in people living with HIV (PWH) found that while it did not reduce the overall incidence of COVID-19, it may lower the risk of severe cases of COVID-19 before vaccination.
- The study analyzed data from 6,905 PWH and included variables such as age, gender, and race, showing that a majority had received COVID-19 vaccinations by the end of the study period.
- Statin therapy demonstrated a potential protective effect against serious COVID-19 cases, as evidenced by a hazard ratio of 0.75, but the results were inconclusive due to fewer cases than expected.
People with human immunodeficiency virus (HIV, PWH) face an increased risk of cardiovascular disease (CVD) compared to the general population. We previously demonstrated that people with (versus without) HIV have higher macrophage-specific arterial infiltration in relation to systemic monocyte activation. We now show that select T lymphocyte subpopulations (naïve CD4 + , effector memory CD4 + , and central memory CD8 + ) are differentially associated with macrophage-specific arterial infiltration among participants with versus without HIV, with evidence of interaction by HIV status.
View Article and Find Full Text PDFBackground: Cytomegalovirus (CMV) seropositivity is associated with poor outcomes, including physical function impairment, in people without HIV. We examined associations between CMV IgG titer and physical function in virologically suppressed people with HIV (PWH).
Methods: REPRIEVE is a double-blind randomized trial evaluating pitavastatin for primary prevention of atherosclerotic cardiovascular disease in PWH.
Article Synopsis
- A study of the neuropilin-1 (NRP-1) protein revealed it has a strong link to coronary plaque in people with HIV, as seen in the REPRIEVE trial's proteomics analysis.
- The association of NRP-1 with proteins involved in crucial biological processes like angiogenesis and immune response, as well as host factors (older age, male sex), indicates its importance in health outcomes.
- NRP-1 is linked to higher risks of various cancers and mortality, particularly related to type 2 myocardial infarction, highlighting its role in serious health issues faced by individuals with HIV.